Stay up-to-date with the latest news and information from the drug testing industry by subscribing to Results, our monthly newsletter.
Your Privacy Choices | Privacy Notices | Privacy Shield | Terms | Language Assistance / Non-Discrimination Notice | Asistencia de Idiomas / Aviso de no Discriminación | 語言協助 / 不䈚視通知
Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks — ® and ™ — are the property of their respective owners. © 2000-2023 Quest Diagnostics Incorporated. All rights reserved.
On Wednesday, February 29, 2012, the Drug Enforcement Administration (DEA) issued a final order to extend the temporary scheduling of the five synthetic cannabinoids into Schedule I drugs of the Controlled Substances Act (CSA). This extension will span through August 29th, 2012 or until rule making proceedings are completed, whichever comes first.
The proposed rule would permanently classify the five synthetic cannabinoids as Schedule I drugs.
Click here to review the document in the Federal Register.
For more information about drug testing, visit our website.